BioForce Nanosciences Holdings, Inc.
BFNH · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 8.16 | 0.35 | -0.01 | 0.00 |
| FCF Yield | -0.12% | -0.18% | -0.12% | -0.15% |
| EV / EBITDA | -176.40 | -123.32 | -96.86 | -83.38 |
| Quality | ||||
| ROIC | 23.19% | 37.57% | 60.93% | -12.90% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.03 | 0.03 | 0.02 | 0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 8.21% | -81.83% | -2.56% | 3.93% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | -0.46 | -0.21 | -2.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |